RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection

Introduction: Thymomas are rare intrathoracic malignancies that may be aggressive and difficult to treat. Knowledge and level of evidence for treatment strategies are mainly based on retrospective studies or expert opinion. Currently there is no strong evidence that postoperative radiotherapy after complete resection of localized thymoma is associated with survival benefit in patients. RADIORYTHMIC is a phase III, randomized trial aiming at comparing postoperative radiotherapy versus surveillance after complete resection of Masaoka-Koga stage IIb/III thymoma. Systematic central pathologic review will be performed before patient enrollment as per the RYTHMIC network pathway. Patients and Methods: Three hundred fourteen patients will be included; randomization 1:1 will attribute either postoperative radiotherapy (50-54 Gy to the mediastinum using intensity-modulated radiation therapy or proton beam therapy) or surveillance. Stratification criteria include histologic grading (thymoma type A, AB, B1 vs B2, B3), stage, and delivery of preoperative chemotherapy. Patient recruitment will be mainly made through the French RYTHMIC net work of 15 expert centers participating in a nationwide multidisciplinary tumor board. Follow-up will last 7 years. The primary endpoint is recurrence-free survival. Secondar y objectives include overall survival, assessment of acute and late toxicities, and analysis of prognostic and predictive biomarkers. Results: The first patient will be enrolled in January 2021, with results expected in 2028. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

The RADIORYTHMIC trial aims to compare postoperative radiotherapy with surveillance for patients with localized thymoma, with a primary endpoint of recurrence-free survival. The study will include 314 patients, with a systematic central pathologic review before enrollment and recruitment mainly through a network of 15 expert centers in France. Follow-up will last for 7 years with results expected in 2028.